Abstracts tagged "tocilizumab and Biologics"

Abstract Number: 1331 • 2019 ACR/ARP Annual Meeting
No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Anja Strangfeld¹, Yvette Meissner ², Martin Schaefer ³, Lisa Baganz ², Matthias Schneider ⁴, Elke Wilden ⁵, Silke Zinke ⁶ and Angela Zink ⁷, ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁵Rheumatologist, Cologne, Germany, ⁶Rheumatologist, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: Spontaneous reports of nine facial paralyses and five facial pareses made by healthcare professionals from Europe have recently prompted EMA’s Pharmacovigilance Risk Assessment Committee…
Abstract Number: 1396 • 2019 ACR/ARP Annual Meeting
Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Jennie Best ³, Steve Zlotnick ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Understanding persistence of biologic therapies and factors associated with discontinuation can help inform treatment decisions for patients with rheumatoid arthritis (RA). We sought to…
Abstract Number: 1427 • 2019 ACR/ARP Annual Meeting
Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Jennie Best¹, Lenore Tominna ¹ and Ibrahim Abbass ¹, ¹Genentech, Inc., South San Francisco, CA
Background/Purpose: The EULAR and ACR clinical guidelines recommend switching to a different disease-modifying antirheumatic drug (DMARD) when biologic-treated patients experience treatment failure or toxicity. Lack…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].